Analyst firms · Leerink Partners · AMYT

Leerink Partners AMYT price target and rating history

Amryt Pharma plc (AMYT) · Health Care

Leerink Partners rates Amryt Pharma plc (AMYT) Outperform with a $10 price target, as of its latest action on Mar 10, 2022. It has published 3 rating actions on AMYT since August 2021, including 0 upgrades and 0 downgrades.

Current rating
Outperform
Price target
$10
Median target, all firms
Too few
Actions on AMYT
3

Leerink Partners price target on AMYT

$22$16$1020222023202420252026
Leerink Partners price target on AMYT, each point a stated target, August 2021 to March 2022.

Every Leerink Partners rating on AMYT

Questions about Leerink Partners and AMYT

What is Leerink Partners's price target for AMYT?
Leerink Partners's latest stated price target for Amryt Pharma plc (AMYT) is $10, from its action on Mar 10, 2022.
What is Leerink Partners's rating on AMYT?
Leerink Partners rates AMYT Outperform, a bullish rating, as of Mar 10, 2022.
When did Leerink Partners last change its view on AMYT?
On Mar 10, 2022, Leerink Partners raises its price target to $10 from $9, keeps Outperform.

All Leerink Partners ratingsAMYT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.